youtube_live
Q2 2027 earnings • released • Revenue beat +1.47%
See resultschevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
¥4,455.00
arrow_upward
+1.25%(+55.00) 1D
Nov 18, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
¥4,455
High
¥4,615
Low
¥4,370
Mkt. cap
207.34B
Avg. vol.
97.32K
Volume
327.70K
Dividend
2.81%
Quarterly dividend
¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.51
52-wk high
¥5,040
52-wk low
¥3,500
EPS
¥270
Shares outstanding
46.72M
No. of employees
2K
Open
¥4,455
High
¥4,615
Low
¥4,370
Mkt. cap
207.34B
Avg. vol.
97.32K
Volume
327.70K
Dividend
2.81%
Quarterly dividend
¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.51
52-wk high
¥5,040
52-wk low
¥3,500
EPS
¥270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
ChartMill
·
46 minutes ago
S&P 500 Postmarket Gainers: PANW, CRWD and OKTA Extend After-Hours Gains
FXStreet
·
34 minutes ago
Dow Jones Industrial Average drops as UnitedHealth and Nvidia fall
BeInCrypto
·
1 hour ago
S&P 500 Breaks Critical Support: Is a Bigger Stock Market Crash Coming?
Traders Union
·
1 hour ago
Peter Tuchman: S&P 500 loses $2.5 trillion in market cap over five days
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp